Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmacological agent and method of treatment

a technology of a drug and a treatment method, applied in the direction of biocide, heterocyclic compound active ingredients, organic compounds of the group 3/13 element, etc., can solve the problems of plantar ulcers and plantar warts, vulnerable to specific antiviral attacks, etc., to achieve the effect of effectively eliminating chemotherapeutic agents, supplying the energy required for drug elimination, and high levels of p170 protein

Inactive Publication Date: 2006-04-06
NOVACTYL
View PDF5 Cites 56 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017] It is among the objects of the present invention to provide a compound which can retard the growth and proliferation of target viruses or cells by blocking the activity of metal ion-containing proteins and proteases.
[0018] Another object of the present invention to provide a compound which can retard the growth and proliferation of target infective organisms including bacteria, fungi, parasites or other infective agents by blocking the activity of metal ion-containing proteins.
[0019] Another object of the present invention is to provide a compound which can retard the growth and proliferation of target viruses or cells by blocking the activity of transition metal ion-containing protein structures such as zinc finger, zinc ring proteins, iron-finger or iron-ring proteins or enzymes associated with replication.

Problems solved by technology

Moreover, papilloma virus can cause plantar ulcers as well as plantar warts.
The hepatitis C virus is not integrated with DNA and thus may be vulnerable to attack by specific antivirals.
Furthermore, since the products can chelate metals, such as iron, they have a role in metal toxicity states, such as iron or lead toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmacological agent and method of treatment
  • Pharmacological agent and method of treatment
  • Pharmacological agent and method of treatment

Examples

Experimental program
Comparison scheme
Effect test

example 8

Treatment of Metastatic Cancer

[0116] The subject is a 62 year old Caucasian male with metastatic colon cancer. The subject presented with an enlarged lymph node in the neck. The lymph node was putting pressure on nerves causing a drooping of the subjects right eye lid. Subsequent testing such as CAT scan and MRI indicated that the lymph node was cancerous. Treatment was initiated with 500 mg of picolinic acid in capsule form, by mouth twice daily. Within 72 hours the lymph node was significantly reduced in size upon palpation, with an estimated reduction of over 50% in mass with concomitant lessening of the droop in the eyelid. An aspiration needle biopsy of the lymph node was attempted but had to be repeated due to the fact that the pathologist was withdrawing necrotic tissue from the lymph node. The subject remains on 500 mg picolinic acid twice daily and is tolerating treatment well. The protocol includes increasing the dosage up to 2000 mg per day, or more, if required.

example 9

Fusaric Acid Effect on Cells with Increased P-Protein Activity

[0117] Multidrug resistance (MDR) is a formidable obstacle to effective cancer chemotherapy. Studies have indicated that MDR is a phenomenon in which resistance to one drug is associated with resistance to a variety of unrelated drugs. Thus, even when a combination of chemotherapeutics is used, patients may exhibit concurrent resistance to some or all of the drugs, leading ultimately to failure of therapy.

[0118] One of the primary contributors to MDR is a glycoprotein denoted P-glycoprotein of molecular weight 170 Kdal, also know as P170. P-glycoprotein or P170 acts as a pump, effectively eliminating chemotherapeutic agents from the cell interior to the extracellular space. Although drug-sensitive cells are destroyed during the initial and subsequent courses of chemotherapy, drug resistance cells, containing elevated levels of P-glycoprotein, emerge, multiply and eventually lead to death of the host.

[0119] P-glycoprote...

example 10

Use of Fusaric Acid to Reduce the Expression of Retroviral mRNA Levels

[0121] By using Kirsten (K) sarcoma retrovirus-transformed NRK cells it was shown in preliminary experiments that fusaric acid reduces the expression of retroviral mRNA levels. Furthermore, it also may be shown that the combination of fusaric acid and interferon-gamma results in a potent inhibition of K sarcoma virus mRNA expression in K-NRK cells.

[0122] Identification of fusaric acid as a substance that can inhibit expression of mRNA controlled by a retroviral promoter is a great interest because of the importance of retroviruses, such as the human immunodeficiency virus (HIV), in animal and human disease. Although the biology of K-virus and HIV is different, fusaric acid may be effective in controlling HIV viral expression. Furthermore, the combination of fusaric acid plus interferon-gamma may be much more potent in inhibiting HIV expression in human monocytes and other infected cells. Thus, this inventions is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

An antiproliferative, antiinflammatory, antiinfective, immunization agent of a metal ion chelating agent such as picolinic acid, analogs or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth, replication or inflammatory response. The preparations can be administered systemically or topically. The products can be used to reduce systemic levels of metals in disease states such as Wilson's disease, iron or lead toxicity. The preparations have antineoplastic, antiviral, antiinflammatory, analgesic antiangiogenic and antiproliferative effects and are used in the treatment of warts, psoriasis, acne, cancers, sunburn, inflammatory responses, untoward angiogenesis and other diseases and in the prevention of sexually transmitted diseases such as genital warts, herpes and AIDS.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of application Ser. No. 09 / 127,620, filed Aug. 1, 1998, which is a continuation-in-part of application Ser. No. 08 / 843,157, filed Apr. 11, 1997, now abandoned, which is a continuation in part of application Ser. No. 08 / 581,351, filed Dec. 29, 1995, now U.S. Pat. No. 5,767,135, and which claims priority to provisional application Ser. No. 60 / 024,221, filed Oct. 22, 1996 and to provisional application Ser. No. 60 / 026,992, filed Sep. 20, 1996.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] None BACKGROUND OF THE INVENTION [0003] The invention relates to the treatment of and immunization against proliferative diseases, inflammatory diseases and pain. More specifically the invention relates to the use of metal chelating materials including, picolinic acid, fusaric acid, their derivatives, analogs and related chemicals as pharmacological and / or biological response modifier agen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/555C07F5/06A61K31/44A61K31/4402A61K31/505A61K45/06
CPCA61K31/44A61K31/4402A61K31/505A61K45/06A61K2300/00A61K31/425
Inventor FERNANDEZ-POL, JOSE A.
Owner NOVACTYL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com